08.08.23 -- The 2 Factors Driving A Surge In Aptamer Use In Drug Discovery

For small biopharma businesses, it is nearly impossible to manage every aspect of the development process in-house. Outsourcing provides the flexibility to change capacity and adjust timings.

The increasing complexity of the drugs currently in clinical development has created mounting pressure for companies hoping to surmount the myriad of challenges that typify these therapeutic modalities.

A pharmaceutical company sought a development and manufacturing partner to assist with an in-licensed product originating from an emerging pharma company, a molecule in clinical Phase 2/3 trials.

As we look forward to the future of drug development, a panel comprising industry consultants and early development experts discussed examining new short- and long-term CDMO and supply chain strategies.